Shenzhen Gnotobio Biotechnology Co., Ltd. (hereinafter referred to as "Gnotobio Biotechnology"), a comprehensive experimental animal platform company dedicated to providing disease animal models, drug screening models, germ-free laboratory animals, and related services to research institutions, hospitals, pharmaceutical companies, and other clients, recently announced the completion of its Pre-A round of financing totaling tens of millions of RMB.

As an enterprise deeply committed to the laboratory animal field, Gnotobio made a remarkable appearance at this industry gathering with its core products and services. We engaged in in-depth exchanges with experts from various sectors, jointly envisioning the future development of laboratory animal science.

On January 24, 2026, Shenzhen Gnotobio Biotechnology Co., Ltd. successfully held its 2025 year-end team building event under the theme "Together, We Go Far; United, We Win" at the picturesque Tongsha Park in Dongguan. All colleagues gathered together to reflect on the past year amidst summaries and laughter, and to look ahead to the future in an atmosphere warm with shared purpose and vibrant with passion. They spent an extraordinary day together, forging firm confidence and renewed vitality for

From July 5 to 6, 2025, the 2025 International Digestive Disease Forum (IDDF) was successfully held at the Hong Kong Convention and Exhibition Centre, bringing together leading experts and scholars from around the world in the fields of digestive diseases and gut microbiome research to discuss the latest advances in cutting-edge technologies and clinical translation.

From June 6 to 8, 2025, the highly anticipated China Gut Microbiome Conference was grandly held in Ningbo. As a major academic event in the field of gut microbiome research, the conference brought together top experts and enterprises from both domestic and international arenas to discuss the future directions of microbiome research innovation and clinical application development.